

## Nanotaxi® publications (April 2017)

Colombani T, Peuziat P, Dallet L, Haudebourg T, Mével M, Berchel M, Lambert O, Habrant D and **Pitard B**. Self-assembling complexes between binary mixtures of lipids with different linkers and nucleic acids promote universal mRNA, DNA and siRNA delivery. *J. Control Release*. (2017) doi: 10.1016/j.jconrel.2017.01.041

Habrant D, Peuziat P, Colombani T, Dallet L, Gehin J, Goudeau E, Evrard B, Lambert O, Haudebourg T, Pitard B. Design of Ionizable Lipids To Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA. *J Med Chem*. (2016) 59:3046-62.

Le Loigne V, Belon C, Goulard C, Accard g, Bernut A, **Pitard B**, Gaillard JL, Kremer L, Herrmann JL Blanc-Potard AB. MgtC as a host-induced factor and vaccine candidate against Mycobacterium abscessus infection. *Infect Immun*. (2016) 84 : 2895-2903

Mével M, Haudebourg T, Colombani T, Peuziat P, Dallet L, Chatin B, Lambert O, Berchel M, Montier T, Jaffrès P-A, Lehn P and Pitard B. Important role of phosphoramido linkage in imidazole-based dioleoyl helper lipids for liposome stability and primary cell transfection. *J Gene Med* (2016) 18:3-15.

Richard-Fiardo P, Hervouet C, Marsault R, Franken PR, Cambien B, Guglielmi J, Warnez-Soulie J, Darcourt J, Pourcher T, Colombani T, Haudebourg T, Peuziat P, Pitard B, Vassaux G. Evaluation of tetrafunctional block copolymers as synthetic vectors for lung gene transfer. *Biomaterials*. (2015) 45:10-7

Chatin B, Mével M, Devallière J, Dallet L, Haudebourg T, Peuziat P, Colombani T, Berchel M, Lambert O, Edelman A, Pitard B. Liposome-based Formulation for Intracellular Delivery of Functional Proteins. *Mol Ther Nucleic Acids*. (2015) Jun 23;4:e244

Le Moigne V, Rottman M, Goulard C, Barteau B, Poncin I, Soismier N, Canaan S, Pitard B, Gaillard JL, Herrmann JL. Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: the Mycobacterium abscessus model. *Vaccine*. (2015) 33: 2118-24.

Arnaoty A, Gouilleux-Gruart V, Casteret S, Pitard B, Bigot Y, Lecomte T. Reliability of the nanospheres-DNA immunization technology to produce polyclonal antibodies directed against human neogenic proteins. *Mol Genet Genomics*. (2013) 288: 347-63

David S, Passirani C, Carmoy N, Morille M, Mevel M, Chatin B, Benoit JP, Montier T, Pitard B. DNA nanocarriers for systemic administration: characterization and in vivo bioimaging in healthy mice. *Mol Ther Nucleic Acids*. (2013) Jan 8;2:e64.

David S, Montier T, Carmoy N, Resnier P, Clavreul A, Mével M, Pitard B, Benoit JP, Passirani C. Treatment efficacy of dna lipid nanocapsules and dna multimodular systems after systemic administration in a human glioma model. *J Gene Med*. (2012) 14:769-775

Beilvert F, Tissot A, Langelot M, Mevel M, Chatin B, Lair D, Magnan A, Pitard B. DNA/amphiphilic block copolymer nanospheres reduce asthmatic response in a mouse model of allergic asthma. *Hum Gene Ther*. (2012) 23: 597-608

Beilvert F, Mével , Châtin B, Pitard B. Local siRNA delivery by non viral vectors. *Journal of Drug Delivery Science and Technology*. (2012) 22: 17-27

## Nanotaxi® publications (April 2017)

David S, Resnier P, Guillot A, Pitard B, Benoit JP, Passirani C. siRNA LNCs - A novel platform of lipid nanocapsules for systemic siRNA administration. *Eur J Pharm Biopharm.* (2012) 81:448-452

Arnaoty A, Pitard B, Bateau B, Bigot Y, Lecomte T. Novel approach for the development of new antibodies directed against transposase-derived proteins encoded by human neogenes. *Methods Mol Biol.* (2012) 859:293-305.

Mével M, Sainlos M, Chatin B, Oudrhiri N, Hauchecorne M, Lambert O, Vigneron JP, Lehn P, Pitard B, Lehn JM. Paromomycin and neomycin B derived cationic lipids: Synthesis and transfection studies. *J Control Release.* (2012) 158:461-469

Cambien B, Richard-Fiardo P, Karimjee BF, Martini V, Ferrua B, Pitard B, Schmid-Antomarchi H, Schmid-Alliana A. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR $\beta$  in colorectal carcinoma. *PLoS One.* (2011) 6:e28842.

Richard-Fiardo P, Cambien B, Beilvert F, Pitard B, Schmid-Antomarchi H, Schmid-Alliana A. Effect of Fractalkine-Fc delivery in experimental lung metastasis using DNA /704 nanospheres. *Cancer Gene Ther* (2011) 18:761-772

Le Bihan O, Chèvre R, Pitard B, and Lambert O. Probing the mechanism of action of cationic lipid/DNA lipoplexes at a nanometric scale. *Nucleic Acids Res* (2011), 39 1595-1609

Chèvre R, Le Bihan O, Beilvert F, Chatin B, Bateau B, Mével M, Lambert O, Pitard B. Amphiphilic Block Copolymers Enhance the Cellular Uptake of DNA Molecules through a Facilitated Plasma Membrane Transport. *Nucleic Acids Res* (2011), 39 1610-1622

Cany J, Bateau B, Tran L, Gauttier V, Archambeau O, Couty JP, Turlin B, Pitard B, Vasseaux G, Ferry N, Conchon S. AFP-specific immunotherapy Impairs Growth of Autochthonous Hepatocellular Carcinoma in Mice. *J Hepatol* (2011) 54, 115-121

Biliczki P, Girmatsion Z, Brandes RP, Harenkamp S, Pitard B, Charpentier F, Hébert TE, Hohnloser SH, Baró I, Nattel S, Ehrlich JR. Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction. *Heart Rhythm.* (2009) 6:1792-801.

Labas R, Beilvert F, Bateau B, David S, Chèvre R, Pitard B. Nature as a source of inspiration for cationic lipid synthesis. *Genetica.* (2010) 138:153-68.

Leblond AL, Naud P, Forest V, Gourden C, Sagan C, Romefort B, Mathieu E, Delorme B, Collin C, Pages JC, Sensebe L, Pitard B, Lemarchand P. Developing cell therapy techniques for respiratory disease: Intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. *Hum Gene Ther.* (2009) 20:1329-43.

McIlroy, D., Bateau, B., Cany, J., Richard, C. Gourden, P Cochon, S. and Pitard, B. DNA/amphiphilic block copolymer nanospheres promote low dose DNA vaccination. *Mol Ther.* (2009) 17, 1473-1481

Bateau, B., Chevre, R., Letrou-Bonneval, E., Labas, R., Lambert, O. and Pitard, B. physicochemical parameter of non-viral vectors that govern transfection efficiency. *Curr Gene Ther.* (2008) 8, 313-323

## Nanotaxi® publications (April 2017)

Pitard, B. Convergence of opposite sciences for the future development of non viral gene therapy. *Curr Gene Ther* (2008) 8, 295

Piron, J., Le Quang, K., Leoni, A.L., Desigaux, L., Amirault, J.C., Pitard, B., Escande, D. and Charpentier, F. Biological pacemaker engineered by non-viral gene transfer for complete atrioventricular block. *Mol Ther* (2008) 16, 1937-1943

Letrou-Bonneval, E., Chevre, R., Lambert, O., Costet, P., Andre, C., Tellier, C. and Pitard, B. Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes. *J. Gene Med.* (2008) 10, 1198-1209

Desigaux, L., Sainlos, M., Lambert, O., Chèvre, R., Letrou-Bonneval E., Lehn, P., Lehn, J.M. and Pitard B. Self-assembled lamellar complexes formed by lipidic aminoglycoside derivatives and siRNA promote efficient RNA interference. *Proc. Natl. Acad. Sci. USA* (2007) 104, 16534-16539